Cytokine–Induced Alteration of Platelet and Hemostatic Function

A number of nonplatelet–specific cytokines that augment platelet recovery following chemo/radiotherapy have been described. The members of the interleukin 6 (IL–6) family have properties that influence the hematopoietic system beyond their modest thrombocytopoietic effects. Studies performed in a ca...

Full description

Saved in:
Bibliographic Details
Published in:Stem cells (Dayton, Ohio) Ohio), 1996, Vol.14 (S1), p.154-162
Main Authors: Burstein, Samuel A., Peng, Jinpeng, Friese, Paul, Wolf, Roman F., Harrison, Paul, Downs, Tamyra, Hamilton, Karen, Comp, Philip, Dale, George L.
Format: Article
Language:English
Subjects:
Activation
Animals
Antibodies, Monoclonal
Bleeding
Bleeding Time
Blood Platelets - drug effects
Blood Platelets - metabolism
Canine
Chromatography, Gel
Dogs
Endothelium, Vascular - drug effects
Endothelium, Vascular - metabolism
Fibrinogen - metabolism
Flow cytometry
Hemostasis
Humans
Interleukin 6
Interleukin-6 - metabolism
Interleukin-6 - pharmacology
Mice
Platelet Activation - drug effects
Platelet Aggregation - drug effects
Platelets
Protein Binding
Protein S - metabolism
Recombinant Proteins - metabolism
Recombinant Proteins - pharmacology
Thrombin - metabolism
Thrombin - pharmacology
Thrombocytopenia - drug therapy
Thromboplastin - biosynthesis
Thrombopoietin
Thrombopoietin - metabolism
Thrombopoietin - pharmacology
Time Factors
von Willebrand Factor - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A number of nonplatelet–specific cytokines that augment platelet recovery following chemo/radiotherapy have been described. The members of the interleukin 6 (IL–6) family have properties that influence the hematopoietic system beyond their modest thrombocytopoietic effects. Studies performed in a canine model with IL–6 have shown that this factor augments plasma fibrinogen and von Willebrand factor (vWf) concentrations and decreases the level of free protein S. IL–6 appears to decrease the bleeding time in thrombocytopenic dogs, although this effect does not seem to be due to a direct influence of the factor on endothelial vWf or tissue factor production. The factor does not directly alter platelet function in vitro, but when administered to dogs, it increases the sensitivity of the platelets to activation by thrombin. Normal platelets injected into IL–6–treated dogs, and platelets from IL–6–treated dogs injected into normal animals, survive normally. Following injection of either IL–6 or the more specific thrombocytopoietic cytokine thrombopoietin (TPO), IL–6 increases platelet responsiveness to thrombin–induced activation to a greater extent than does TPO. The data show that IL–6 has certain properties that might be construed as prohemostatic, and these properties may prove to be useful clinically.
ISSN:1066-5099
1549-4918
DOI:10.1002/stem.5530140720